BioElectronics Corporation Chairman Outlines Strategic Initiatives and Potential Legal Action
TL;DR
BioElectronics Corporation is launching its RecoveryRx product into the veterinary market, targeting a new customer base.
The RecoveryRx product is being re-focused on channels where it is paid for by the system, not the patient, such as the VA system.
The company's products provide effective pain relief for both human and animal suffering, with a focus on reducing pain and improving quality of life.
BioElectronics Corporation is in the final stages of obtaining the necessary litigation financing to pursue legal action against Mundipharma for breach of contract.
Found this article helpful?
Share it with your network and spread the knowledge!
BioElectronics Corporation (OTC: BIEL), a medical technology products developer, is making strategic moves to expand its market presence and address past challenges, according to a recent update from Chairman Richard Staelin, PhD. The company is refocusing its efforts on channels where its RecoveryRx product can be covered by insurance or paid for by the system, rather than out-of-pocket by patients.
A key initiative involves partnering with a service-disabled veteran-owned small business to introduce RecoveryRx into the VA system, bolstered by a testimonial from a Congressional Medal of Honor recipient. This approach aims to provide relief to veterans while potentially boosting sales volumes.
The company is also targeting the veterinary market, leveraging clinical findings that demonstrate the device's efficacy in improving the quality of life for older dogs with osteoarthrosis. A presentation to a major corporate-owned veterinary clinic chain has led to a formal product evaluation, which could open doors to approximately 1,000 clinics in the United States.
On the clinical front, a study on the effectiveness of BioElectronics' device in managing post-surgical carpal tunnel release pain has been accepted for publication, potentially expanding its medical applications. This development could enhance the product's credibility in the medical community and open new market opportunities.
In a significant business development, BioElectronics is considering legal action against Mundipharma Southeast Asia for breach of contract. The company alleges that Mundipharma failed to meet guaranteed purchase volumes and product registration obligations in a five-year contract. BioElectronics is in the final stages of securing litigation financing, indicating a strong commitment to pursuing its contractual rights.
These developments highlight BioElectronics' efforts to overcome past setbacks, including a terminated contract with Synergy Corporation, and to focus on its core competencies in R&D and manufacturing. The company continues to seek partnerships with third-party experts who have the capital and marketing expertise to effectively reach customers seeking pain relief solutions.
The update underscores BioElectronics' determination to expand its market presence, validate its technology through clinical research, and protect its business interests. These actions could potentially lead to increased sales, broader market acceptance, and improved financial performance, which may be of interest to current and prospective investors in the medical technology sector.
Curated from NewMediaWire
